Dharma Biologics | Bengaluru, India
Drug–device combinations fail when teams pretend they are either drugs or devices. In reality, they are neither. They are coupled systems in which formulation chemistry, mechanical tolerances, human factors, regulatory classification, and supply-chain discipline interact continuously. A change that is trivial in a vial can destabilize a pen injector. A formulation that is stable in bulk can become unusable when exposed to shear, dwell time, or elastomer contact inside a delivery system. Regulatory pathways multiply, documentation fragments, and accountability blurs.
Dharma Biologics built its drug–device capability specifically to resolve this ambiguity. We do not treat combination products as a downstream packaging exercise or a device program with a drug attached. We treat them as integrated systems that must be designed, validated, and governed as a single entity from development through commercial supply.
At the core of our approach is a simple premise: delivery is part of the product. Dose accuracy, injection force, usability, and long-term stability are not secondary attributes. They are critical quality attributes, and they must be engineered deliberately.
Regulatory Reality of Combination Products
Combination products exist at the intersection of regulatory regimes, and this intersection is where many programs stall. Depending on jurisdiction and product design, oversight may involve drug authorities, device authorities, or coordinated review bodies. Expectations around design controls, human factors, change management, and post-market surveillance differ materially from those applied to drug products alone.
Dharma Biologics structures combination programs to withstand this complexity by aligning regulatory strategy, technical development, and documentation from the outset. We establish clear primary mode of action determinations, define the applicable regulatory frameworks early, and ensure that development artifacts support both drug and device expectations. This avoids the common late-stage scramble where teams attempt to retrofit design history files or usability data onto a program that was never designed to support them.
Formulation Meets Mechanics
The central technical challenge in drug–device combinations is the interaction between formulation properties and mechanical delivery. Viscosity, surface tension, particulate content, and protein stability directly influence injection force, dose accuracy, and device reliability. Conversely, device geometry, spring force, needle dimensions, and internal flow paths impose shear, pressure, and interfacial exposure on the formulation.
At Dharma Biologics, formulation development for combination products is conducted with full awareness of the intended delivery system. We evaluate how formulation concentration affects viscosity and how that viscosity translates into injection force across temperature ranges. We study shear profiles within cartridges, syringes, and pen mechanisms to identify conditions that may induce aggregation or denaturation. We assess dwell times within the device and their impact on adsorption and leachables. This bidirectional analysis prevents the common failure mode where a formulation is finalized before device constraints are understood.
Autoinjectors: Reliability Under Stress
Autoinjectors introduce a layer of mechanical complexity that demands rigorous control. Spring-driven systems generate rapid pressure changes that can stress sensitive biologics. Needle insertion dynamics influence patient experience and dose delivery. Activation mechanisms must function reliably across a wide range of environmental and handling conditions.
Dharma Biologics supports autoinjector programs by integrating device selection, formulation characterization, and fill-finish execution into a single development stream. We evaluate device performance under worst-case viscosity and temperature conditions, recognizing that real-world use rarely mirrors laboratory assumptions. Injection force profiles are mapped against formulation behavior to ensure consistent delivery without excessive shear. Device assembly and final packaging are performed under controlled conditions to preserve both mechanical integrity and sterility.
Fixed and Variable Dose Pen Systems
Pen injectors, particularly variable dose systems, place stringent demands on dose accuracy, reproducibility, and long-term stability. Small deviations in cartridge dimensions, plunger movement, or formulation rheology can translate into clinically meaningful dosing errors. Over time, mechanical wear, elastomer relaxation, and formulation changes can alter device behavior.
Dharma Biologics approaches pen systems as precision instruments rather than commodity devices. We validate dose accuracy across the full range of intended settings, accounting for temperature, storage duration, and user variability. We study how formulation properties evolve over shelf life and how those changes affect dose delivery. Change control is structured to recognize that even minor adjustments to components or suppliers can have outsized effects on system performance.
Prefilled Systems and Integrated Fill–Finish
Prefilled syringes and cartridges occupy a middle ground between traditional injectables and fully integrated devices. They reduce preparation steps for the end user but introduce new risks related to siliconization, plunger behavior, and container–closure integrity. These risks are amplified when products are intended for self-administration or long-term storage.
Dharma Biologics integrates prefilled system development with aseptic fill-finish execution, ensuring that device requirements are reflected in filling parameters, stoppering processes, and inspection strategies. Siliconization methods are selected based on formulation sensitivity, with careful control of silicone load and droplet behavior. Container–closure integrity is evaluated longitudinally, recognizing that plunger relaxation and barrel deformation can evolve over time.
Human Factors and Usability Engineering
Combination products ultimately interface with people, not laboratories. Human factors failures—misuse, confusion, incomplete dose delivery—are among the most common causes of post-market issues. These failures often trace back to development decisions that prioritized technical feasibility over usability.
Dharma Biologics incorporates human factors considerations early, aligning device selection and design inputs with the intended user population. We support usability studies that examine not only whether a device can be used, but how it is actually used under realistic conditions. Feedback from these studies informs both device configuration and labeling strategy, reducing the risk of downstream corrective actions.
Manufacturing and Assembly Discipline
Drug–device combination manufacturing demands tighter coordination than either drug or device production alone. Assembly tolerances, environmental controls, and material traceability must align with both sterility and mechanical requirements. A lapse in either domain can compromise the entire product.
Our assembly operations are designed to preserve sterility while maintaining mechanical precision. We control environmental conditions to protect sensitive formulations during device integration. Assembly processes are validated to ensure repeatability, and in-process controls are selected to detect drift before it propagates. Documentation links each assembled unit back to both drug and device component lots, supporting robust traceability.
Change Management Across Coupled Systems
Change management is particularly challenging for combination products because changes rarely affect only one domain. A new elastomer formulation may alter extractables, injection force, and shelf-life stability simultaneously. A manufacturing scale change may influence both fill accuracy and device performance.
Dharma Biologics manages change through integrated impact assessment. Proposed changes are evaluated across formulation, device mechanics, regulatory classification, and user interaction. This holistic view prevents the piecemeal approvals that often lead to cumulative risk. Sponsors gain confidence that changes improve the system rather than merely shifting risk elsewhere.
Commercial Supply and Lifecycle Considerations
As combination products move into commercial supply, pressures intensify. Volumes increase, cost optimization becomes attractive, and supply chains lengthen. These forces can destabilize systems that were marginally robust during development.
Dharma Biologics designs combination product programs with commercial reality in mind. We favor conservative operating windows, proven component suppliers, and assembly processes that scale without introducing new failure modes. Through the CDMO Network, we support redundancy and capacity expansion while maintaining standardized quality and documentation frameworks. This enables growth without fragmentation.
Why Combination Products Fail—and Why Ours Don’t
Across the industry, combination product failures follow familiar patterns: late integration of device considerations, underestimation of formulation–mechanical interactions, fragmented regulatory strategy, and superficial human factors work. These failures are not inevitable. They are the result of treating coupled systems as separate problems.
Dharma Biologics avoids these outcomes by insisting on integration from the start. Formulation scientists, device engineers, manufacturing teams, and regulatory specialists work from a shared understanding of the product as a single system. Decisions are made with full awareness of downstream consequences. Problems are surfaced early, when they are still solvable.
Closing Perspective
Drug–device combinations represent the future of injectable therapy, but they demand a level of discipline that exceeds traditional drug manufacturing. Success requires respect for mechanics, chemistry, people, and regulation simultaneously. Dharma Biologics operates in this space deliberately, bringing structure to complexity and control to systems that others treat as black boxes.
Based in Bengaluru, and operating within a broader CDMO Network, we deliver combination product capabilities that are not merely functional, but durable. Programs built here are designed to survive scale, scrutiny, and time.
Order is the source. Delivery is the proof.
ಸಂಯೋಜನೆಯಲ್ಲಿ ನಿಯಂತ್ರಣ. ವಿತರಣೆಯಲ್ಲಿ ನಿಖರತೆ.